Skip to main content

Table 1 Baseline Patient Characteristics

From: Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis

Total Number of Patients 25
Age (years), mean (SD) 52 (9.9)
Females (percent) 22 (88%)
Race n (%)
 Caucasian 10 (40%)
 Black 4 (16%)
 Hispanic 5 (20%)
 Asian 4 (16%)
 Other 2 (8%)
Seropositive n (%) 22 (88%)
Disease Duration (years), mean (SD) 10.4 (9.7)
BMI, mean (SD) 31.0 (10.8)
Prednisone at Baseline n (%) 7 (28%)
csDMARDs at Baseline n (%) 18 (72%)
    Methotrexate 13 (52%)
    Sulfasalazine 4 (16%)
    Hydroxychloroquine 4 (16%)
    Leflunomide 4 (16%)
bDMARDs before Baseline n (%)
 TNF inhibitor 8 (32%)
 IL-6 inhibitor 1 (4%)
 Anti-CTLA4-IgG 2 (8%)
 None of the Above 14 (56%)
Comorbidities (number), mean (SD) 3.8 (2.6)
  1. SD Standard Deviation, RF Rheumatoid Factor, ACPA Anti-Citrullinated Protein
  2. Antibody; BMI = Body Mass Index; csDMARDs = Conventional Synthetic Disease
  3. Modifying Anti-Rheumatic Drugs; bDMARDs = Biological DMARDs